Search research articles
Contact Us
Filters
Showing results (131-140 of 145) with videos related to
Page
of 15
Sort By:
Hemasphere
|
October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance
Stephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Bone Marrow Transplantation
|
April 29, 2021
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Matthew J Rees, Peter Mollee, Jun Yen Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
European Journal of Haematology
|
February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.
The Medical Journal of Australia
|
May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
Robert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
BMJ Open
|
June 17, 2017
Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial
Claire M Rickard, Nicole M Marsh, Joan Webster, et al.
American Journal of Hematology
|
March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Nature Reviews. Nephrology
|
December 5, 2018
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 145) with videos related to
Sort By:
Page
of 15
Hemasphere
|
October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance
Stephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Bone Marrow Transplantation
|
April 29, 2021
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Matthew J Rees, Peter Mollee, Jun Yen Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2025
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
European Journal of Haematology
|
February 14, 2025
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 31, 2020
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf, et al.
The Medical Journal of Australia
|
May 14, 2020
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
Robert Weinkove, Zoe K McQuilten, Jonathan Adler, et al.
BMJ Open
|
June 17, 2017
Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial
Claire M Rickard, Nicole M Marsh, Joan Webster, et al.
American Journal of Hematology
|
March 16, 2022
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, et al.
Nature Reviews. Nephrology
|
December 5, 2018
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
Nelson Leung, Frank Bridoux, Vecihi Batuman, et al.
Page
of 15